OBR Daily Commentary

forumImage

Is Fairness in the Eye of the Beholder? Pfizer Citizen Petition Looking for Fair and Level Playing Field Between Biologics and Biosimilars

(FDA Law Blog) Aug 29, 2018 - An interesting Citizen Petition popped up earlier this week in which pharma giant Pfizer has requested FDA guidance on sponsor communications about biosimilar products.

Read Article arrow

Winston Wong, PharmD (Posted: September 08, 2018)

quotesWhile there may be some truth that there is a lack of confidence with biosimilar products, I believe that the confidence level is increasing, thus not the reason for the slow uptake in utilization. I believe that the true reason for the slow uptake is due to contracting and rebate levels increasing with the reference product so that there is little motivation for any stakeholder to switch to the biosimilar product. The power of the rebate is so woven into the selection process that unless the biosimilars start to represent more significant deeper discounts than they do today, uptake will continue to be slow.quotes

Add Comment 1 Comment
forumImage

Administration To 'Unleash' Medicare Advantage Plans' Bargaining Power On Some Drug Prices

(KHN Morning Briefing) Aug 8, 2018 - As a negotiation tool, Medicare Advantage plans will now be able to require patients getting drugs in a doctor's office or the hospital to try lower-cost medicines before moving up to more expensive ones in a process called step therapy.

Read Article arrow

Winston Wong, PharmD (Posted: August 13, 2018)

quotesSpecific to cancer care, it will be interesting to see how the discussion plays out with the allowance of so-called "Step-Therapy" and the requirement to cover anything listed in the NCCN guidelines. Will the two be allowed together? quotes

Add Comment 1 Comment
forumImage

Sorry About Your Stage 3 Cancer. Here's A Bill For $21,000 In Charges You Thought Were Covered

(Los Angeles Times) Aug 7, 2018 - When Michele Brough was diagnosed with Stage 3 breast cancer in April, her oncologist wasted no time in reaching out to her insurer, Anthem Blue Cross and Blue Shield, to obtain pre-approval for a drug that would strengthen her immune system to better withstand chemotherapy.

Read Article arrow

Winston Wong, PharmD (Posted: August 13, 2018)

quotesUnfortunately, stories and reports like these are all too common. I have to wonder as I read this. Was the misfortune due to the mis-interpretation of Neulasta Onpro vs. Neupogen? The majority of Neulata is under the medical benefit. I can see the Neupogen being forced through specialty and self-administered. Nevertheless, the timing for responses was poor.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...